|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07D 471/14 | (2006.01) |
| A61K 31/437 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2473510 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10757878.3 |
| Date of filing the European patent application | 2010-09-02 | |
| (97) | Date of publication of the European application | 2012-07-11 |
| (45) | Date of publication and mention of the grant of the patent | 2014-07-23 |
| (46) | Date of publication of the claims translation | 2014-10-27 |
| (86) | Number | PCT/US2010/047621 |
| Date | 2010-09-02 |
| (87) | Number | WO 2011/028864 |
| Date | 2011-03-10 |
| (30) | Number | Date | Country code |
| 239501 P | 2009-09-03 | US |
| (72) |
PURANDARE, Ashok V., US
GREBINSKI,James W., US
HART, Amy, US
INGHRIM, Jennifer, US
SCHROEDER, Gretchen, US
WAN, Honghe, US
|
| (73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | JAK2 inhibitoriai ir jų panaudojimas mieloproliferacinių ligų bei vėžio gydymui |
| JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER |
| Payment date | Validity (years) | Amount | |
| 2022-08-23 | 13 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2023-09-02 |